Uncategorized October 4, 2010 0 A Unique Roadblock for Pfizer’s Osteoarthritis Drug We’ve heard of drugs underperforming in clinical trials, but is it possible for a drug to over-perform?
Uncategorized September 17, 2010 0 No Shortage of Hopefuls in the Multibillion-Dollar Blood Thinner Business Patients hoping for a new alternative to the blockbuster blood thinner Plavix will have to wait a bit longer for a verdict on a promising candidate.
Uncategorized April 5, 2010 0 Immune-Based Treatments for Brain Cancer Post Impressive Early-Stage Results Approximately 19,000 individuals in the US are diagnosed with primary brain cancers each year.
Uncategorized November 29, 2009 1 Cancer Vaccines: Investing Opportunities Beyond Dendreon Despite the setbacks and pitfalls experienced by early-stage pioneers in the cancer immunotherapy / therapeutic cancer vaccine space, recent advancements and study results are encouraging.
Uncategorized October 27, 2009 0 Ligand to Buy Struggling Metabasis Ligand Pharmaceuticals has agreed to buy the struggling Metabasis Therapeutics for $3.2 million in cash.
Uncategorized September 24, 2009 0 Melanoma Drug Called a “Breakthrough” After Study Scientists are calling Plexxikon’s experimental skin cancer drug a “breakthrough” after it successfully shrank tumors in clinical trial patients.
Uncategorized August 8, 2009 0 New Software Brings Scientists Together Imagine thousands of scientists across the globe collaborating to find a cure for cancer, or create a new malaria vaccine.